AU2021360767A1 - Methods of treating fibrosis - Google Patents

Methods of treating fibrosis Download PDF

Info

Publication number
AU2021360767A1
AU2021360767A1 AU2021360767A AU2021360767A AU2021360767A1 AU 2021360767 A1 AU2021360767 A1 AU 2021360767A1 AU 2021360767 A AU2021360767 A AU 2021360767A AU 2021360767 A AU2021360767 A AU 2021360767A AU 2021360767 A1 AU2021360767 A1 AU 2021360767A1
Authority
AU
Australia
Prior art keywords
fibrosis
hydrogen
taladegib
treatment
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021360767A
Other languages
English (en)
Other versions
AU2021360767A9 (en
Inventor
Miguel De Los Rios
Anita J. DIFRANCESCO
John Hood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endeavor Biomedicines Inc
Original Assignee
Endeavor Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endeavor Biomedicines Inc filed Critical Endeavor Biomedicines Inc
Publication of AU2021360767A1 publication Critical patent/AU2021360767A1/en
Publication of AU2021360767A9 publication Critical patent/AU2021360767A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021360767A 2020-10-13 2021-10-13 Methods of treating fibrosis Pending AU2021360767A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Publications (2)

Publication Number Publication Date
AU2021360767A1 true AU2021360767A1 (en) 2023-04-27
AU2021360767A9 AU2021360767A9 (en) 2024-02-08

Family

ID=81209448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021360767A Pending AU2021360767A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Country Status (8)

Country Link
US (4) US11628167B2 (https=)
EP (1) EP4229828A4 (https=)
JP (1) JP2023546536A (https=)
KR (1) KR20230107568A (https=)
CN (1) CN116349204A (https=)
AU (1) AU2021360767A1 (https=)
CA (1) CA3198661A1 (https=)
WO (1) WO2022081661A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
AU2024230449A1 (en) * 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (https=) 1977-06-03 1981-03-07 Pfizer
MY117098A (en) 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
ES2377430T3 (es) 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010017240A2 (en) 2008-08-04 2010-02-11 Amgen Inc. Aurora kinase modulators and methods of use
MX2011004683A (es) 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
BRPI0921777A2 (pt) 2008-11-17 2016-01-12 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9970935B2 (en) * 2014-02-06 2018-05-15 The Brigham And Women's Hospital, Inc. Uses of GLI1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
JP2018535238A (ja) 2015-11-30 2018-11-29 イグナイタ インコーポレイテッド 局所製剤
EP3536320A4 (en) * 2016-11-04 2020-07-29 Impact Therapeutics, Inc APPLICATION OF A HEDGEHOG TRACT INHIBITOR FOR THE TREATMENT OF FIBROTIC DISEASES
US11154541B2 (en) 2018-06-29 2021-10-26 The Trustees Of Indiana University Methods for treating aortic valve stenosis with a hedgehog pathway inhibitor
EP3823618A1 (en) * 2018-07-19 2021-05-26 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
AU2024230449A1 (en) 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Also Published As

Publication number Publication date
CN116349204A (zh) 2023-06-27
CA3198661A1 (en) 2022-04-21
US12213974B2 (en) 2025-02-04
US20230201195A1 (en) 2023-06-29
JP2023546536A (ja) 2023-11-02
US20240342170A1 (en) 2024-10-17
KR20230107568A (ko) 2023-07-17
US12295954B2 (en) 2025-05-13
US11628167B2 (en) 2023-04-18
EP4229828A4 (en) 2024-08-28
EP4229828A1 (en) 2023-08-23
AU2021360767A9 (en) 2024-02-08
WO2022081661A1 (en) 2022-04-21
US20220265650A1 (en) 2022-08-25
US20250235452A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
US12213974B2 (en) Methods of treating fibrosis
US12605377B2 (en) Methods of treating fibrosis
AU2024230449A1 (en) Methods of treating fibrosis
JP6170040B2 (ja) ピルフェニドン及び選択された患者における抗線維化療法
JP2022514121A (ja) がんの処置における使用のためのｂｔ１７１８
Donohue et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD
US20160324829A1 (en) Combination therapy with parp inhibitors
ES3039974T3 (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
CN108883311A (zh) 布罗莫结构域和额外末端蛋白抑制剂组合疗法
US20090029966A1 (en) Combination therapy with parp inhibitors
TWI750129B (zh) 作為血液學毒性生物標記之ｇｄｆ-１５
US20200368246A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
EP4301350A1 (en) Treatment of copper disorders
Ebbehøj et al. Recovery after laparoscopic parastomal hernia repair
Sugihara et al. 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol
Ohta et al. Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective,‘real-world’comparison with amlodipine
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
US20080280867A1 (en) Combination therapy with parp inhibitors
WO2023108140A1 (en) Method of treating cancer having an activated hedgehog pathway
WO2025189041A1 (en) Methods of treating fibrosis
JP2005531622A5 (https=)

Legal Events

Date Code Title Description
SREP Specification republished